Joachim Yahalom

List of Publications by Year
in descending order

161 papers	9,802 citations	44069 48 h-index	38395 95 g-index
162 all docs	162 docs citations	162 times ranked	7466 citing authors

#	Article	IF	Citations
1	Treatment for Primary CNS Lymphoma: The Next Step. Journal of Clinical Oncology, 2000, 18, 3144-3150.	1.6	572
2	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2014, 89, 854-862.	0.8	479
3	A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 2001, 97, 616-623.	1.4	402
4	Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology, 2013, 31, 3971-3979.	1.6	386
5	How I treat extramedullary acute myeloid leukemia. Blood, 2011, 118, 3785-3793.	1.4	385
6	Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. Journal of Clinical Oncology, 2007, 25, 4730-4735.	1.6	359
7	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.8	303
8	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphomaâ€"Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	0.8	259
9	Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood, 2004, 104, 3483-3489.	1.4	258
10	Normalization of pre-ASCT, FDG-PET imaging with second-line, nonâ€"cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 2012, 119, 1665-1670.	1.4	258
11	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 2003, 102, 1989-1996.	1.4	235
12	Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. Archives of Neurology, 2005, 62, 1595-600.	4.5	232
13	Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 2010, 116, 4934-4937.	1.4	228
14	T-Cellâ€"Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood, 1998, 91, 1083-1090.	1.4	217
15	Primary bone lymphoma: Treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer, 2006, 106, 2652-2656.	4.1	200
16	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Journal of the National Cancer Institute, 2012, 104, 357-370.	6.3	187
17	Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology, 2007, 69, 1178-1182.	1.1	170
18	Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Molecular Therapy, 2018, 26, 2542-2552.	8.2	169

#	Article	IF	Citations
19	Non-Hodgkin's Lymphomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 484-560.	4.9	161
20	Non-Hodgkinâ€™s Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1282-1303.	4.9	144
21	Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsyâ€proven primary refractory Hodgkin's disease. British Journal of Haematology, 2004, 124, 645-652.	2.5	142
22	Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2018, 101, 521-529.	0.8	138
23	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. British Journal of Haematology, 2009, 146, 158-163.	2.5	134
24	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 101, 794-808.	0.8	128
25	Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. Journal of Neuro-Oncology, 2009, 91, 315-321.	2.9	108
26	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1067-1079.	4.9	107
27	Pulmonary Complications in Lymphoma Patients Treated with High-Dose Therapy and Autologous Bone Marrow Transplantation. The American Review of Respiratory Disease, 1992, 146, 485-491.	2.9	102
28	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 3109-3117.	1.6	97
29	Intensity-modulated radiotherapy for lymphoma involving the mediastinum. International Journal of Radiation Oncology Biology Physics, 2005, 62, 198-206.	0.8	96
30	Highâ€dose chemoâ€radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of preâ€transplant functional imaging. British Journal of Haematology, 2010, 148, 890-897.	2.5	90
31	Radiation Therapy for Chloroma (Granulocytic Sarcoma). International Journal of Radiation Oncology Biology Physics, 2012, 82, 1816-1822.	0.8	90
32	Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer, 1993, 71, 2342-2350.	4.1	86
33	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood, 2018, 132, 1635-1646.	1.4	86
34	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	1.4	85
35	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
36	Low-grade MALT lymphoma of the stomach: a review of treatment options. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1093-1103.	0.8	75

#	Article	IF	Citations
37	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 652-669.	0.8	71
38	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia, 2021, 35, 130-142.	7.2	70
39	[18F]FDG-Positron Emission Tomography Coregistration With Computed Tomography Scans for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2011, 81, 615-622.	0.8	69
40	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
41	Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 5240-5247.	1.6	65
42	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Advances, 2020, 4, 4669-4678.	5.2	64
43	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood, 2016, 128, 1458-1464.	1.4	61
44	Long-Term Outcomes and Patterns of Relapse of Early-Stage Extranodal Marginal Zone Lymphoma Treated With Radiation Therapy With Curative Intent. International Journal of Radiation Oncology Biology Physics, 2015, 92, 130-137.	0.8	60
45	Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). European Journal of Haematology, 2005, 75, 90-97.	2.2	56
46	Radiation treatment planning techniques for lymphoma of the stomach. International Journal of Radiation Oncology Biology Physics, 2005, 62, 745-751.	0.8	54
47	Early experience using salvage radiotherapy for relapsed/refractory nonâ€Hodgkin lymphomas after CD19 chimericÂantigen receptor (CAR)ÂT cell therapy. British Journal of Haematology, 2020, 190, 45-51.	2.5	51
48	Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. Journal of Clinical Oncology, 2008, 26, 1858-1864.	1.6	50
49	Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal of Neuro-Oncology, 2019, 144, 553-562.	2.9	48
50	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.8	46
51	Disparities in survival by insurance status in patients with <scp>H</scp>odgkin lymphoma. Cancer, 2015, 121, 3515-3524.	4.1	44
52	Overexpression of basic fibroblast growth factor (FGFâ€“2) downregulates Bclâ€“2 and promotes apoptosis in MCFâ€“7 human breast cancer cells. Breast Cancer Research and Treatment, 1999, 56, 151-165.	2.5	43
53	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica, 2016, 101, 1237-1243.	3.5	42
54	Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer. Cancer, 1990, 66, 844-847.	4.1	40

#	Article	IF	Citations
55	Long-Term Cardiac and Pulmonary Complications of Cancer Therapy. Hematology/Oncology Clinics of North America, 2008, 22, 305-318.	2.2	40
56	Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leukemia and Lymphoma, 2016, 57, 2575-2583.	1.3	39
57	Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 102, 53-58.	0.8	39
58	Challenges and opportunities in primary CNS lymphoma: A systematic review. Radiotherapy and Oncology, 2017, 122, 352-361.	0.6	38
59	Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Medicine, 2019, 8, 58-66.	2.8	38
60	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	6.3	38
61	Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncology, The, 2011, 12, 118-119.	10.7	37
62	Early-Stage Classic Hodgkin Lymphoma: TheÂUtilization of Radiation Therapy and Its Impact on Overall Survival. International Journal of Radiation Oncology Biology Physics, 2015, 93, 684-693.	0.8	35
63	NCCN GuidelinesÂ® Insights: Hodgkin Lymphoma, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 322-334.	4.9	35
64	Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leukemia and Lymphoma, 2014, 55, 795-801.	1.3	34
65	Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 102, 314-319.	0.8	33
66	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 2257-2265.	1.6	32
67	Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 544-548.	1.6	31
68	Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. Journal of Clinical Oncology, 2016, 34, 1443-1447.	1.6	31
69	The concept and evolution of involved site radiation therapy for lymphoma. International Journal of Clinical Oncology, 2015, 20, 849-854.	2.2	30
70	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2019, 104, 501-512.	0.8	30
71	Low-Dose and Limited-Volume Radiotherapy Alone for Primary Dural Marginal Zone Lymphoma: Treatment Approach and Review of Published Data. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1425-1435.	0.8	29
72	Non-Hodgkinâ€™s Lymphomas, Version 3.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1487-1498.	4.9	29

#	Article	IF	Citations
73	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Health Physics, 2014, 106, 229-246.	0.5	27
74	Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. British Journal of Haematology, 2016, 175, 440-447.	2.5	27
75	The role of radiation therapy in the management of primary central nervous system lymphoma. Leukemia and Lymphoma, 2015, 56, 1197-1204.	1.3	26
76	Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 92, 76-83.	0.8	26
77	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
78	Breast Cancer After Hodgkin Disease. JAMA - Journal of the American Medical Association, 2003, 290, 529.	7.4	25
79	Very low utility of surveillance imaging in earlyâ€stage classic <scp>H</scp>odgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer, 2015, 121, 1985-1992.	4.1	25
80	Radiotherapy of Follicular Lymphoma: Updated Role and New Rules. Current Treatment Options in Oncology, 2014, 15, 262-268.	3.0	23
81	Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. Blood Advances, 2018, 2, 649-655.	5.2	22
82	Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1995, 33, 525-528.	0.8	21
83	Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. Radiotherapy and Oncology, 2016, 118, 52-59.	0.6	20
84	The Case for Adjuvant Radiation Therapy in Advanced Hodgkin's Disease. Cancer Investigation, 1996, 14, 361-370.	1.3	19
85	Radiation therapy for leukemia cutis. Practical Radiation Oncology, 2011, 1, 182-187.	2.1	19
86	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20ÂYears of Experience. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1066-1076.	0.8	19
87	Role of Radiation Therapy in Hodgkinâ€™s Lymphoma. Cancer Journal (Sudbury, Mass), 2009, 15, 155-160.	2.0	18
88	A Prospective Study of 18FDG-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 89, 376-383.	0.8	18
89	Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS ONE, 2016, 11, e0155711.	2.5	18
90	Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. Leukemia and Lymphoma, 2020, 61, 3331-3341.	1.3	17

#	Article	IF	Citations
91	Diagnostic and Therapeutic Considerations for Extramedullary Leukemia. Current Oncology Reports, 2020, 22, 75.	4.0	17
92	Involved-site radiotherapy for Helicobacter pyloriâ€“independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Advances, 2021, 5, 1830-1836.	5.2	17
93	Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. International Journal of Radiation Oncology Biology Physics, 2018, 100, 670-678.	0.8	16
94	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology Biology Physics, 2019, 104, 522-529.	0.8	16
95	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. Blood Advances, 2021, 5, 4185-4197.	5.2	15
96	Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. Breast Cancer Research and Treatment, 2001, 70, 27-37.	2.5	14
97	Radiation therapy in the treatment of lymphoma. Current Opinion in Oncology, 1999, 11, 370.	2.4	14
98	Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: Lack of correlation between inhibition of cell growth and MAP kinase activation. , 1998, 177, 411-425.		13
99	Changing role and decreasing size: Current trends in radiotherapy for hodgkinâ€™s disease. Current Oncology Reports, 2002, 4, 415-423.	4.0	13
100	Favorable Early-Stage Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 233-240.	4.9	12
101	Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice on outcome. Leukemia and Lymphoma, 2013, 54, 177-180.	1.3	12
102	Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy. Leukemia and Lymphoma, 2017, 58, 614-622.	1.3	12
103	Management of relapsed and refractory Hodgkin's disease. Seminars in Radiation Oncology, 1996, 6, 210-224.	2.2	11
104	Radiotherapy for Non-Hodgkin Lymphomas. Cancer Journal (Sudbury, Mass), 2020, 26, 217-230.	2.0	11
105	Treatment Options for Hodgkin's Disease During Pregnancy. Leukemia and Lymphoma, 1990, 2, 151-161.	1.3	10
106	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 3382-3390.	5.2	10
107	Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat. Leukemia and Lymphoma, 2007, 48, 1667-1669.	1.3	9
108	Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy. Leukemia and Lymphoma, 2013, 54, 1208-1211.	1.3	9

#	Article	IF	Citations
109	Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. Leukemia and Lymphoma, 2016, 57, 320-327.	1.3	9
110	Hodgkin Disease/Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 594.	4.9	9
111	Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e279-e281.	0.4	8
112	Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 685-689.	0.4	8
113	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilageâ€"Case Report. Frontiers in Oncology, 2017, 7, 284.	2.8	7
114	Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2018, 102, 508-514.	0.8	7
115	Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000â€“2015). Radiotherapy and Oncology, 2022, 173, 179-187.	0.6	7
116	Do not miss a second (and possibly last) chance to cure Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1997, 39, 595-597.	0.8	6
117	Radiation therapy for stage III follicular lymphomaâ€"often ignored, but still effective. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1-2.	0.8	6
118	PETâ€“Computed Tomography for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. PET Clinics, 2011, 6, 165-175.	3.0	6
119	The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Review of Anticancer Therapy, 2011, 11, 1367-1378.	2.4	6
120	Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but â€œsameâ€•(or possibly worse) survival â€“ Reconsidering the misguided trend to omit radiotherapy. Current Hematologic Malignancy Reports, 2014, 9, 212-216.	2.3	6
121	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	5.2	6
122	Preface. Hematology/Oncology Clinics of North America, 2008, 22, xi-xii.	2.2	5
123	Does radiotherapy still have a place in Hodgkin lymphoma?. Current Hematologic Malignancy Reports, 2009, 4, 117-124.	2.3	5
124	Long-Term Cardiac and Pulmonary Complications of Cancer Therapy. Heart Failure Clinics, 2011, 7, 403-411.	2.1	5
125	Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 1074-1082.	1.3	5
126	The presence of a bulky mediastinal mass of 7â€‰cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT. Leukemia and Lymphoma, 2021, 62, 1313-1324.	1.3	5

#	Article	IF	Citations
127	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2020, 136, 17-18.	1.4	5
128	Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.. Blood, 2006, 108, 3057-3057.	1.4	5
129	Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. International Journal of Radiation Oncology Biology Physics, 2020, 106, 279-281.	0.8	4
130	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. Blood, 2019, 134, 1555-1555.	1.4	4
131	Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. Leukemia and Lymphoma, 2020, 61, 1500-1503.	1.3	3
132	In Reply to Scarpelli et al. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1396.	0.8	2
133	Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy. Hematological Oncology, 2021, 39, 304-312.	1.7	2
134	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. Journal of Cancer Education, 2023, 38, 201-205.	1.3	2
135	Comment on: â€œClinical Features, Management, and Prognosis of an International Series of 161 Patients With Limitedâ€Stage Diffuse Large Bâ€Cell Lymphoma of the Bone (the IELSGâ€14 Study)â€. Oncologist, 2014, 19, 1289-1289.	3.7	1
136	Innovative Approaches to Radiation Treatment for Mycosis Fungoides in the Setting of Collagen Vascular Disease. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	1
137	Principles of Radiation Therapy for Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 157-176.	0.2	1
138	Total Body Irradiation. , 2016, , 341-357.e7.		1
139	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 977-978.	0.8	1
140	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. British Journal of Radiology, 2021, 94, 20210285.	2.2	1
141	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2005, 106, 2072-2072.	1.4	1
142	Principles, Indications, and Techniques of Radiation Therapy of Lymphomas. , 2006, , 203-224.		1
143	Total Body Irradiation. , 2012, , 345-360.		1
144	Principles of Radiation Therapy for Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 171-197.	0.2	1

#	Article	IF	Citations
145	Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas. Blood, 2021, 138, 3518-3518.	1.4	1
146	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. Blood, 2020, 136, 1-2.	1.4	1
147	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
148	Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy. Bone Marrow Transplantation, 2022, 57, 1038-1041.	2.4	1
149	Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019. JAMA Health Forum, 2022, 3, e221815.	2.2	1
150	Chemoradiotherapy for primary CNS lymphoma. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 123-136.	0.0	0
151	In Reply to Zhang. International Journal of Radiation Oncology Biology Physics, 2017, 99, 501.	0.8	0
152	Deauville Dubiosity. International Journal of Radiation Oncology Biology Physics, 2020, 106, 16.	0.8	0
153	Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: Characteristics and Treatment Outcome of 19 Cases.. Blood, 2004, 104, 4564-4564.	1.4	0
154	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 2073-2073.	1.4	0
155	Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.. Blood, 2007, 110, 1893-1893.	1.4	0
156	Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.. Blood, 2007, 110, 1649-1649.	1.4	0
157	Principles of Radiation Techniques in Hodgkin Lymphoma. , 2011, , 117-139.		0
158	Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma. , 2011, , 31-44.		0
159	Curative radiation for orbital MZL: how much?. Blood, 2017, 129, 270-271.	1.4	0
160	Radiation Therapy for Patients with Diffuse Large B Cell Richter's Syndrome of CLL. Blood, 2021, 138, 1565-1565.	1.4	0
161	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	1.4	0